Full Press Release Details
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody® technology platform, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in the following virtual investor conferences in August.
BTIG 5th Virtual Biotechnology Conference
Date: Monday, August 9, 2021
Presentation Time: 1:00 p.m. ET.
2021 Wedbush PacGrow Healthcare Virtual Conference
Date: Tuesday, August 10, 2021
Panel Discussion: 1:10 p.m. ET
In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences.
About CytomX Therapeutics
CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. We are developing a novel class of investigational conditionally activated therapeutics, based on our Probody® technology platform, for the treatment of cancer. CytomX has strategic drug discovery and development collaborations with AbbVie, Amgen, Astellas, and Bristol Myers Squibb.
Probody is a U.S. registered trademark of CytomX Therapeutics, Inc.